UCB SA (UCB.BR) Stock Fundamental Analysis
Europe - EBR:UCB - BE0003739530 - Common Stock
255.7 EUR
-1 (-0.39%)
UCB gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 54 industry peers in the Pharmaceuticals industry. UCB has an average financial health and profitability rating. UCB shows excellent growth, but is valued quite expensive already. These ratings would make UCB suitable for growth investing!
1. Profitability
1.1 Basic Checks
UCB had positive earnings in the past year.
UCB had a positive operating cash flow in the past year.
Each year in the past 5 years UCB has been profitable.
In the past 5 years UCB always reported a positive cash flow from operatings.
1.2 Ratios
UCB has a better Return On Assets (7.75%) than 62.96% of its industry peers.
UCB has a Return On Equity (13.76%) which is comparable to the rest of the industry.
Looking at the Return On Invested Capital, with a value of 11.63%, UCB is in line with its industry, outperforming 57.41% of the companies in the same industry.
UCB had an Average Return On Invested Capital over the past 3 years of 4.35%. This is significantly below the industry average of 14.71%.
The 3 year average ROIC (4.35%) for UCB is below the current ROIC(11.63%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.75% | ||
| ROE | 13.76% | ||
| ROIC | 11.63% |
ROA(3y)3.66%
ROA(5y)4.78%
ROE(3y)6.35%
ROE(5y)8.35%
ROIC(3y)4.35%
ROIC(5y)6.33%
1.3 Margins
With a decent Profit Margin value of 19.45%, UCB is doing good in the industry, outperforming 74.07% of the companies in the same industry.
In the last couple of years the Profit Margin of UCB has remained more or less at the same level.
The Operating Margin of UCB (26.58%) is better than 70.37% of its industry peers.
In the last couple of years the Operating Margin of UCB has declined.
Looking at the Gross Margin, with a value of 73.38%, UCB is in line with its industry, outperforming 59.26% of the companies in the same industry.
In the last couple of years the Gross Margin of UCB has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 26.58% | ||
| PM (TTM) | 19.45% | ||
| GM | 73.38% |
OM growth 3Y-15.5%
OM growth 5Y-9.39%
PM growth 3Y-1.86%
PM growth 5Y1.44%
GM growth 3Y-1.62%
GM growth 5Y-0.73%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so UCB is still creating some value.
The number of shares outstanding for UCB remains at a similar level compared to 1 year ago.
The number of shares outstanding for UCB has been increased compared to 5 years ago.
The debt/assets ratio for UCB has been reduced compared to a year ago.
2.2 Solvency
UCB has an Altman-Z score of 5.44. This indicates that UCB is financially healthy and has little risk of bankruptcy at the moment.
UCB has a better Altman-Z score (5.44) than 77.78% of its industry peers.
The Debt to FCF ratio of UCB is 2.43, which is a good value as it means it would take UCB, 2.43 years of fcf income to pay off all of its debts.
With a decent Debt to FCF ratio value of 2.43, UCB is doing good in the industry, outperforming 72.22% of the companies in the same industry.
A Debt/Equity ratio of 0.29 indicates that UCB is not too dependend on debt financing.
UCB's Debt to Equity ratio of 0.29 is fine compared to the rest of the industry. UCB outperforms 64.81% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.29 | ||
| Debt/FCF | 2.43 | ||
| Altman-Z | 5.44 |
ROIC/WACC1.52
WACC7.67%
2.3 Liquidity
A Current Ratio of 1.35 indicates that UCB should not have too much problems paying its short term obligations.
UCB has a Current ratio (1.35) which is comparable to the rest of the industry.
A Quick Ratio of 1.01 indicates that UCB should not have too much problems paying its short term obligations.
UCB has a better Quick ratio (1.01) than 62.96% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.35 | ||
| Quick Ratio | 1.01 |
3. Growth
3.1 Past
UCB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 75.41%, which is quite impressive.
Measured over the past years, UCB shows a decrease in Earnings Per Share. The EPS has been decreasing by -0.86% on average per year.
The Revenue has grown by 25.56% in the past year. This is a very strong growth!
Measured over the past years, UCB shows a small growth in Revenue. The Revenue has been growing by 4.60% on average per year.
EPS 1Y (TTM)75.41%
EPS 3Y-8.45%
EPS 5Y-0.86%
EPS Q2Q%68.9%
Revenue 1Y (TTM)25.56%
Revenue growth 3Y2.12%
Revenue growth 5Y4.6%
Sales Q2Q%24.94%
3.2 Future
UCB is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 27.31% yearly.
The Revenue is expected to grow by 13.38% on average over the next years. This is quite good.
EPS Next Y51.36%
EPS Next 2Y41.05%
EPS Next 3Y36.7%
EPS Next 5Y27.31%
Revenue Next Year22.68%
Revenue Next 2Y18.33%
Revenue Next 3Y16.89%
Revenue Next 5Y13.38%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 39.83, which means the current valuation is very expensive for UCB.
Compared to the rest of the industry, the Price/Earnings ratio of UCB indicates a slightly more expensive valuation: UCB is more expensive than 61.11% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 27.31. UCB is valued slightly more expensive when compared to this.
Based on the Price/Forward Earnings ratio of 25.81, the valuation of UCB can be described as expensive.
Based on the Price/Forward Earnings ratio, UCB is valued a bit more expensive than the industry average as 66.67% of the companies are valued more cheaply.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.85, UCB is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 39.83 | ||
| Fwd PE | 25.81 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, UCB is valued a bit more expensive than 64.81% of the companies in the same industry.
61.11% of the companies in the same industry are cheaper than UCB, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 41.97 | ||
| EV/EBITDA | 20.52 |
4.3 Compensation for Growth
UCB's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of UCB may justify a higher PE ratio.
UCB's earnings are expected to grow with 36.70% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.78
PEG (5Y)N/A
EPS Next 2Y41.05%
EPS Next 3Y36.7%
5. Dividend
5.1 Amount
UCB has a yearly dividend return of 0.37%, which is pretty low.
UCB's Dividend Yield is slightly below the industry average, which is at 3.04.
Compared to an average S&P500 Dividend Yield of 2.40, UCB's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.37% |
5.2 History
The dividend of UCB has a limited annual growth rate of 2.46%.
Dividend Growth(5Y)2.46%
Div Incr Years6
Div Non Decr Years6
5.3 Sustainability
19.82% of the earnings are spent on dividend by UCB. This is a low number and sustainable payout ratio.
UCB's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP19.82%
EPS Next 2Y41.05%
EPS Next 3Y36.7%
EBR:UCB (10/16/2025, 7:00:00 PM)
255.7
-1 (-0.39%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners40.07%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap49.74B
Analysts79.2
Price Target233.58 (-8.65%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.37% |
Yearly Dividend1.36
Dividend Growth(5Y)2.46%
DP19.82%
Div Incr Years6
Div Non Decr Years6
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.91%
PT rev (3m)10.28%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0.32%
EPS NY rev (3m)1.61%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)1.5%
Revenue NY rev (3m)5.16%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 39.83 | ||
| Fwd PE | 25.81 | ||
| P/S | 7.26 | ||
| P/FCF | 41.97 | ||
| P/OCF | 31.56 | ||
| P/B | 5.14 | ||
| P/tB | 45.76 | ||
| EV/EBITDA | 20.52 |
EPS(TTM)6.42
EY2.51%
EPS(NY)9.91
Fwd EY3.87%
FCF(TTM)6.09
FCFY2.38%
OCF(TTM)8.1
OCFY3.17%
SpS35.21
BVpS49.78
TBVpS5.59
PEG (NY)0.78
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.75% | ||
| ROE | 13.76% | ||
| ROCE | 13.73% | ||
| ROIC | 11.63% | ||
| ROICexc | 13.71% | ||
| ROICexgc | 58.2% | ||
| OM | 26.58% | ||
| PM (TTM) | 19.45% | ||
| GM | 73.38% | ||
| FCFM | 17.3% |
ROA(3y)3.66%
ROA(5y)4.78%
ROE(3y)6.35%
ROE(5y)8.35%
ROIC(3y)4.35%
ROIC(5y)6.33%
ROICexc(3y)4.85%
ROICexc(5y)7.22%
ROICexgc(3y)28.31%
ROICexgc(5y)48.18%
ROCE(3y)5.15%
ROCE(5y)7.49%
ROICexcg growth 3Y-25.87%
ROICexcg growth 5Y-16.2%
ROICexc growth 3Y-19.14%
ROICexc growth 5Y-14.38%
OM growth 3Y-15.5%
OM growth 5Y-9.39%
PM growth 3Y-1.86%
PM growth 5Y1.44%
GM growth 3Y-1.62%
GM growth 5Y-0.73%
F-Score9
Asset Turnover0.4
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.29 | ||
| Debt/FCF | 2.43 | ||
| Debt/EBITDA | 1.15 | ||
| Cap/Depr | 61.48% | ||
| Cap/Sales | 5.71% | ||
| Interest Coverage | 16.4 | ||
| Cash Conversion | 64.17% | ||
| Profit Quality | 88.96% | ||
| Current Ratio | 1.35 | ||
| Quick Ratio | 1.01 | ||
| Altman-Z | 5.44 |
F-Score9
WACC7.67%
ROIC/WACC1.52
Cap/Depr(3y)52.98%
Cap/Depr(5y)82.03%
Cap/Sales(3y)5.99%
Cap/Sales(5y)6.61%
Profit Quality(3y)131.69%
Profit Quality(5y)119.05%
High Growth Momentum
Growth
EPS 1Y (TTM)75.41%
EPS 3Y-8.45%
EPS 5Y-0.86%
EPS Q2Q%68.9%
EPS Next Y51.36%
EPS Next 2Y41.05%
EPS Next 3Y36.7%
EPS Next 5Y27.31%
Revenue 1Y (TTM)25.56%
Revenue growth 3Y2.12%
Revenue growth 5Y4.6%
Sales Q2Q%24.94%
Revenue Next Year22.68%
Revenue Next 2Y18.33%
Revenue Next 3Y16.89%
Revenue Next 5Y13.38%
EBIT growth 1Y258.97%
EBIT growth 3Y-13.71%
EBIT growth 5Y-5.23%
EBIT Next Year150.43%
EBIT Next 3Y58.09%
EBIT Next 5Y37.74%
FCF growth 1Y91.13%
FCF growth 3Y-4.61%
FCF growth 5Y9.37%
OCF growth 1Y61.64%
OCF growth 3Y-7.18%
OCF growth 5Y7.09%